Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -29.58M | -24.75M | 53.28M | 53.28M | -26.58M |
| Total Depreciation and Amortization | 705.00K | 788.00K | 902.00K | 902.00K | 976.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.39M | 5.99M | 5.28M | 5.28M | 7.21M |
| Change in Net Operating Assets | 1.03M | -5.23M | 1.34M | 1.34M | -2.25M |
| Cash from Operations | -22.45M | -23.21M | 60.81M | 60.81M | -20.64M |
| Capital Expenditure | -605.00K | -103.00K | -219.50K | -219.50K | -34.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -605.00K | -103.00K | -219.50K | -219.50K | -34.00K |
| Total Debt Issued | 0.00 | 0.00 | 12.24M | 12.24M | 16.18M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 63.00K | 226.00K | 222.00K | 222.00K | 12.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 70.79M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -594.00K | -2.38M | -92.00K | -92.00K | -- |
| Cash from Financing | 70.26M | -2.15M | 12.37M | 12.37M | 16.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.21M | -25.46M | 72.95M | 72.95M | -4.49M |